Enfusion Inc

Enfusion — Q1 2023 Earnings Presentation

20 slides from Enfusion's earnings presentation, May 9, 2023

  1. Slide 1: Enfusion 1Q 2023 Shareholder Letter

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 1Q 2023 Shareholder Letter May 2023

  2. Slide 2: Disclaimer: Forward-Looking Statements

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 (

  3. Slide 3: Dear Shareholders

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 3 Dear Shareholders, Since Enfusion’s founding, navigating challenging environments has been a part of our journey. From the Global Financial Crisis to the COVID pandemic, following each instance of macroeconomic uncertainty, we have

  4. Slide 4: Our mission

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. To help solve investment managers’ evolving business and operational challenges through next generation technology Our mission 4

  5. Slide 5: We simplify and unify the investment management lifecycle

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. …empowering teams to operate in concert CFO COO CIO Portfolio Manager Analysts Traders Compliance Officer Investor Relations Middle Office Back Office We simplify and unify the investment management lifecycle We manage complex workflo

  6. Slide 6: Serving clients across the investment management industry

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 6 Serving clients across the investment management industry Alternative Investment Managers Hedge Funds Private Equity Private Credit Family Offices Institutional Investment Managers Wealth Managers Traditional Asset Managers Mutual F

  7. Slide 7: Purpose-built end-to-end solution

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Purpose-built end-to-end solution 7 Portfolio Management System Order Execution Management System Technology-Powered Services Accounting / General Ledger Analytics • Live details of portfolio positions • Real-time Investment Book of R

  8. Slide 8: Addressing a large and growing market

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Robust growth in Underlying industry Addressing a large and growing market $11.5bn $5.7bn $2.0bn $19bn+ Software & IT services from Investment Management Internal IT spend IT hardware spend Source: IDC’s Worldwide Capital Markets IT S

  9. Slide 9: Client-centric approach: Why we win

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 9 Client-centric approach Why we win One end-to-end solution, one single dataset and source of truth Rapid pace of delivery and evolution Open, flexible and tailored Unique ability to lead with a single solution – and then adjust to a

  10. Slide 10: Q1 2023 key financial highlights

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Q1 2023 key financial highlights $41.0 20.0% YoY Growth Adjusted Free Cash Flow Z00 Total Revenue Z00 Adjusted EBITDA Z00 79.7% FCF Conversion $4.5 $27.7 67.5% Gross Margin Highly attractive SaaS model with combination of scale, growt

  11. Slide 11: Strong growth trends with ongoing profitability

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. $1.8 $5.3 $5.4 $6.8 $5.7 $2.6 $0.8 $4.7 1Q22 2Q22 3Q22 4Q22 1Q23 Adjusted EBITDA Net Income Strong growth trends with ongoing profitability Operating Cash Flow and Adjusted Free Cash Flow $ in millions $34.1 $36.5 $39.2 $40.5 $41.0 1Q

  12. Slide 12: Organic, sticky expansion at scale

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. $137.6 $148.7 $158.7 $164.7 $167.0 1Q22 2Q22 3Q22 4Q22 1Q23 115.8% 121.9% 116.6% 115.4% 110.5% 1Q22 2Q22 3Q22 4Q22 1Q23 Organic, sticky expansion at scale 12 Net Dollar Retention Rate(1) Avg Contract Value 756 793 810 819 813 1Q22 2Q2

  13. Slide 13: Appendix

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Appendix

  14. Slide 14: Consolidated Balance Sheets

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 14 ENFUSION, INC. CONSOLIDATED BALANCE SHEETS (dollars in thousands, except shares and unit amounts and par value) ASSETS Current Assets: Cash and cash equivalents $ 54,598 $ 62,545 Accounts receivable, net 24,356 25,855 Prepaid expen

  15. Slide 15: Consolidated Statements of Operations

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 15 ENFUSION. INC. CONSOLIDATED STATEMENTS OF OPERATIONS (dollars in thousands) (Unaudited) REVENUES: Platform subscriptions $ 37,998 $ 31,551 Managed services 2,744 2,230 Other 229 360 Total revenues 40,971 34,141 COST OF REVENUES: Pl

  16. Slide 16: Consolidated Statements of Cash Flows

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 16 ENFUSION. INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (dollars in thousands) (Unaudited) Cash flows from operating activities : Net income (loss) $ 4,694 $ (12,524) Adjustments to reconcile net income (loss) to net cash provided by

  17. Slide 17: Reconciliations To Non-GAAP Financial Measures

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures 17 The following table reconciles net income to Adjusted EBITDA: The following table reconciles gross profit to adjusted gross profit: ($ in thousands) December 31, 2021 March 30, 2022 Ju

  18. Slide 18: Reconciliations of Non-GAAP Financial Measures

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations of Non-GAAP Financial Measures 18 The following table reconciles operating cash flow to unlevered free cash flow and adjusted free cash flow: The Company’s stock compensation expense was recognized in the following cap

  19. Slide 19: Definitions

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 19 Definitions Non-GAAP Financial Measures In addition to financial measures prepared in accordance with GAAP, this presentation and the accompanying tables include Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjus

  20. Slide 20: Definitions Continued

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 20 Definitions Continued Key Metrics: In connection with the management of our business, we identify, measure and assess a variety of key metrics. The key metrics we use in managing our business are set forth below. Annual Recurring R

Enfusion — Q1 2023 Earnings Presentation on 6ix